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Abstract:
Background:  Fibromyalgia is a common chronic
musculoskeletal pain syndrome, however its characteristics,
diagnosis and management have not always been well
understood.  There is now increasing understanding of the
pathophysiological mechanisms of fibromyalgia and
development of more effective management strategies.
Objective:  To explain the characteristics and diagnostic
features of fibromyalgia.  A discussion of current
management strategies is included.
Discussion:  Fibromyalgia patients have a central pain
system problem that results in widespread musculoskeletal
pain, and many other disabling features in the absence of
tissue damage.  The ability to exclude other pathology and
recognize the disorder is important, as there are very real
management options available.  Management is most
effective as a multidisciplinary, layered approach.  It is
important to involve the patient in their own treatment
program, to enhance its success.
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INTRODUCTION
Fibromyalgia is a common condition characterised by
chronic, widespread musculoskeletal pain and tenderness
in the absence of tissue damage.  It affects between 3-5%
of the population in industrialised nations and results in
significant burden on the health systems of those countries,
as well as large amounts of lost employment time and a
significant number of compensation claims1,2.
In general, fibromyalgia has been poorly understood by
the health care industry and at best, management has been
unclear and often ineffectual.  Recently, there has been an
increase in our knowledge of the pathophysiological
mechanisms behind the clinical presentation of
fibromyalgia and this has led to better management
strategies.  This has resulted in an improvement in quality
of life for those with fibromyalgia and an increased sense
that there are indeed effective therapeutic strategies to
deal with the disorder.
AETIOLOGY
The clinical features of fibromyalgia result from dysfunction
of the pain-related components of the nervous system.
This results in increased sensitivity of pain-related nerves
to the degree that otherwise innocuous stimuli will result
in pain3-5.  This process of sensitisation has its origins in
the spinal cord and central nervous system but the clinical
effects are in the musculoskeletal system.  This is where
abnormal tenderness and muscular tightness both in the
periphery and spinal regions, characterise the problem.
Other nerve pathways also interact with the sensitised
pain system and result in unwanted signalling.  For instance,
the A-beta mechanoreceptors gain access to the activated
pain system and allow otherwise innocuous stimuli derived
from normal movement or maintenance of posture to invoke
pain.  These mechanoreceptor stimuli from deeply placed
para-spinal structures provide the dorsal horn input to
initiate reflex referred pain phenomena.  This referred pain
helps explain the widespread nature of the fibromyalgic
pain symptoms6,7.  It also explains the change in regional
pain threshold, another feature of fibromyalgia, as decrease
in pain threshold is also part of reflex “referred pain”.
Although is it still unclear what causes the sensitisation of
the central pain system, it is likely to be related to abnormal
activation of the body’s hormonal stress responses
associated with the hypothalamic-pituitary-adrenal axis
and central neurochemical transmission in nerve pain
pathways7,8.
There is some evidence that fibromyalgia is more common
in some families, with family members of patients displaying
a higher than expected incidence of the condition, as well
as related conditions including irritable bowel syndrome,
migraine headache and mood disorders9,10.
Fibromyalgia can develop spontaneously or after exposure
to an identifiable trigger, possibly in a person who is
genetically predisposed.  Triggers are described as
environmental stressors and can include injury, especially
to the axial skeleton, or illness (e.g. Parvovirus or Hepatitis
C).  The problem doesn’t necessarily need to be severe but
often involves anxiety, incapacity or bed rest.  Fibromyalgia
can also be triggered by stressful situations and major life
events and people who develop the disorder can often
underestimate the role of stress in their illness11.  Other
situations associated with an increased risk of fibromyalgia
range from concurrent chronic illness such as rheumatoid
arthritis, systemic lupus erythematosus or hypothyroidism,
through to rupture of silicone breast implants6,9,10,12.ACO
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DIAGNOSIS
The current American College of Rheumatology consensus
criteria for the classification of fibromyalgia require chronic,
widespread musculoskeletal pain and the presence of at
least 11 tender points on testing at 18 specified sites
(Figure 1, Table 1).  The pain must occur in all 4 quadrants
of the body and the axial skeleton.  Tender points are
distinct predictable anatomical sites that are normally more
sensitive to pressure than the surrounding tissue.  They
are different to trigger points in that they are not sites of
tissue damage, tightness or pathology, do not produce
spontaneous pain, and are usually unknown to the patient.
Tender points are seen in many different tissues types,
such as muscle, fat and attachment of tendons to bones
and reflect global change in pain perception through the
process of sensitisation.
Figure 1:  Tender point sites for digital palpation. Figure
reproduced with permission G. Littlejohn.
To perform a tender point examination, pressure should
be applied to each of these sites with the examiner’s thumb
or index and middle fingers held together - slowly
increasing the pressure until approximately four kilograms
of pressure is applied (approximately the amount of
pressure required to blanch the examiner’s nail bed).  The
patient needs to describe actual pain with the pressure,
rather than just discomfort, for the tenderpoint to be
considered positive.  A patient must accrue 11 out of
possible 18 positive tenderpoints to meet the official
classification criteria.  It is well understood however, that
many patients who clearly suffer from the symptoms of
fibromyalgia have less than 11 of these tenderpoints.
Many people have fluctuating levels of musculoskeletal
tenderness, with different testing times, stress levels and
medications all having an effect on the number of positive
tenderpoints.  Men also have a generally higher
tenderness threshold and less often have a complete “set”
of positive tenderpoints despite clearly having
symptomatic disease – which may partially explain why
more women than men receive the label of fibromyalgia.
Other symptoms of fibromyalgia include chronic fatigue,
altered sleep patterns resulting in unrefreshing sleep,
memory disturbance, postural hypotension, dizziness and
emotional distress.  Symptoms often fluctuate in their
intensity and anatomical location, with many patients
experiencing “flares” alternating with periods of relatively
lower activity.  Flares can be induced or worsened by
situations such as emotional stress, physical exertion,
concurrent illness or even seasonal changes.
OTHER CLINICAL FEATURES
Fibromyalgia can co-exist with any other illness and many
other problems can mimic fibromyalgia.  Hence, other
causes for the symptoms of fibromyalgia must be ruled out
before the diagnosis can be confirmed.  Many patients with
fibromyalgia also satisfy the criteria for other syndromes
such as chronic fatigue syndrome and gulf war illness.
This has prompted some researchers to consider them as
all being different parts of a chronic multisystem illness
spectrum, with the principal features of chronic pain and
fatigue.
The syndrome is closely associated with many other stress
– related problems such as regional chronic pain, irritable
bowel syndrome, interstitial cystitis, temporomandibular
joint dysfunction, migraine and tension headaches, multiple
chemical sensitivities and depression.
On further physical examination, there is usually obvious
allodynia (pain in response to non-noxious stimuli such as
light touch, movement or posture), and there may be
muscle tightness with limited range of motion of spinal
segments.  Patients often complain of regional swelling
that can fluctuate in site and severity, and can be difficult
to objectively assess.  There is no evidence of inflammation,
muscle wasting, degenerative change, neurological
abnormality or systemic illness that would explain the
symptoms or signs.
MANAGEMENT
Management of patients with fibromyalgia begins with
patient education as to the nature of the illness.  Many
sufferers feel immediate benefit from identification of the
problem and reassurance as to the benign and often slowly
improving natural history.  It is important to counsel
patients about the benefits of a healthy lifestyle,
incorporating advice about diet, exercise and relaxation.
Referral to support networks such as the Arthritis
Foundation is also very helpful.
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Sleep hygiene advice can help those who have problems
with unrefreshing sleep and should include suggestions
of relaxation before bedtime, setting and adhering to regular
bedtimes and avoiding exercise, caffeine or alcohol before
retiring for the night.
Physical therapies play a role particularly in helping with
regional symptoms, for instance paraspinal muscle
stiffness.  Many develop trigger points in addition to the
generalised fibromyalgic tenderness and these may require
the usual therapeutic approaches.  However, treatment
needs to be gentler than in someone without fibromyalgia
to avoid significant post-treatment pain.  Many patients
find complimentary therapies, such as yoga, t’ai chi,
massage, naturopathy and acupuncture also useful.
Medication therapy for fibromyalgia is available and is
best used in combination with the above non-
pharmacological approaches.  Tricyclic antidepressant
medications, particularly amitriptyline, have been most
useful in easing pain and fatigue, as well as improving sleep
quality.  They only provide partial relief however and are
only effective in approximately one third of patients23,24.
Some other antidepressant medications may also have a
small positive effect.  Simple analgesics, such as
paracetamol, can help to ease minor pain, but do not offer
Graded low-impact aerobic exercise is an important
therapeutic intervention in fibromyalgia.  Patients are often
extremely de-conditioned and this requires beginning with
very low-grade exercise, perhaps in a heated pool.  The
intensity is slowly increased over weeks or months until
the subject is able to exercise at aerobic levels for over 30
minutes almost daily.  It is helpful to let the patient choose
the type of low-impact exercise they prefer, such as walking
or swimming, as this will then suit their lifestyle and be more
likely to be sustained.  This type of program has been
proven to improve pain and fatigue levels in many large
controlled studies and is one of the most effective available
interventions13-17.  High-intensity exercise is often poorly
tolerated and may aggravate symptoms.
Psychological therapeutic options have been shown to
help the pain, fatigue and distress of fibromyalgia18.  Simple
stress management advice can be of benefit to many
patients, however sometimes is not a powerful enough
intervention to cause change.  Cognitive Behaviour Therapy
(CBT) and similar formal approaches address areas such as
relaxation training, personal sense of control, coping
strategies and goal setting, and can translate into significant
improvement in pain, functional abilities and other features
of fibromyalgia19-22.
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Table 1:  Clinically useful sites for evaluating tenderness.  These sites are more sensitive to palpation than adjacent
sites in pain-free individuals and significantly more sensitive in patients with widespread pain when they are
termed tender points.  Regional pain syndromes are associated with increased sensitivity in tender points located
within the painful region.  
 
Occiput 
 
 
Bilateral, at the suboccipital muscle insertions. 
 
 
Low Cervical 
 
 
Bilateral, at the anterior aspects of the intertransverse spaces at C5 – C7. 
 
 
Trapezius 
 
 
Bilateral, at the mid-point of the upper border. 
 
 
Supraspinatus 
 
 
Bilateral, at origins, above the scapula spine near the medial border. 
 
 
Second Rib 
 
 
Bilateral, at the second costochondral junctions, just lateral to the junctions on upper 
surfaces. 
 
 
Lateral 
Epicondyle 
 
 
Bilateral, 2cm distal to the epicondyles. 
 
 
Gluteal 
 
 
Bilateral, in upper outer quadrants of buttocks in anterior fold of muscle. 
 
 
Greater 
Trochanter 
 
 
Bilateral, posterior to trochanteric prominence. 
 
 
Knee 
 
 
Bilateral, at the medial fat pad proximal to the joint line. 
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long-term effective control.  Non-steroidal anti-
inflammatory drugs have no proven benefit.  There are
some medications that may show promise but require
further research into their effectiveness in this situation,
for example tropisetron25.
It is important in any treatment plan for fibromyalgia for
the patient to feel they have input in managing their
disease.  This builds their sense of control over the
symptoms and encourages maintenance of therapies that
require active involvement such as exercise.  Once patients
feel that their own actions have an impact on the severity
of symptoms, they feel more reassured and empowered,
which leads to further improvement in features such as
distress.
CONCLUSIONS
Fibromyalgia is a common, debilitating disorder with
widespread and fluctuating symptoms.  It is important to
recognise the diagnosis, so that the patient has access to
an appropriate therapeutic strategy.  Management of
fibromyalgia is best carried out using a multimodal, holistic
approach, with involvement of the patient’s local doctor.
The patient themselves needs to be encouraged to take an
active role in their own treatment which augments any
other therapeutic benefits.
SUMMARY OF IMPORTANT POINTS
• The features of fibromyalgia result from an abnormal
sensitisation of the pain-related central nervous system.
• Symptoms can be multiple, widespread and fluctuating,
with flares induced or worsened in situations of physical or
emotional stress.
• Management is most effective when synergistic multimodal
treatments are used by a multidisciplinary team involving
the patient’s local doctor.
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